Literature DB >> 24199756

When should a mechanical tricuspid valve replacement be considered?

Sameh M Said1, Harold M Burkhart2, Hartzell V Schaff1, Jonathan N Johnson3, Heidi M Connolly4, Joseph A Dearani1.   

Abstract

BACKGROUND: Isolated mechanical tricuspid valve replacement (mTVR) is uncommon, early mortality is reported to be high, and little is known regarding the long-term outcome. We sought to evaluate the long-term outcome of mTVR.
METHODS: From 1980 to 2007, isolated mTVR was performed in 64 patients (33 men) at our institution; the median age was 45.5 years (6-71 years). There were 2192 tricuspid valve (TV) repairs and 137 isolated bioprosthetic TV replacements during the same time interval. Valve dysfunction was caused by congenital TV abnormality in 45 patients (70%), carcinoid heart disease in 13 (20%), traumatic TV regurgitation in 3 (5%), and other reason in 3 (5%). Twenty-three patients (36%) had at least 1 previous cardiac procedure (TV repair in 8 and bioprosthetic TV replacement in 7).
RESULTS: Mechanical prostheses used included Starr-Edwards (before 1993) in 36 patients (56%) and bileaflet prostheses in 28 (44%). Concomitant procedures included atrial septal defect closure in 28 (44%), arrhythmia surgery in 11 (17%), and pulmonary valvectomy for carcinoid disease in 10 patients (16%). Early mortality occurred in 5 patients (7.8%). Early morbidity included a permanent pacemaker in 9 (14%) and reexploration for bleeding in 2 patients (3%). Mean follow-up was 6 years (maximum 22.4 years). Five- and 10-year survival was 65% and 58%, respectively. There was no valve-related mortality. Late morbidity included valve thrombosis in 5 patients (8%); 3 were managed nonoperatively and 2 underwent TV rereplacement.
CONCLUSIONS: Isolated mTVR still leads to increased early mortality. A mechanical valve can be considered in select situations when anticoagulation is necessary and in the presence of good right ventricular function.
Copyright © 2014 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24199756     DOI: 10.1016/j.jtcvs.2013.09.043

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  5 in total

1.  A comparative study on the results of beating and arrested heart isolated tricuspid valve surgery: A cross-sectional study.

Authors:  Leila Bigdelu; Ali Azari; Zarrin Mashayekhi; Maliheh Dadgarmoghaddam; Vafa Baradaran Rahimi
Journal:  Health Sci Rep       Date:  2022-06-16

2.  Dehiscence and embolization of CorMatrix tricuspid valve replacement in the setting of infective endocarditis: a case report.

Authors:  Anna N Tomdio; Melissa Y Y Moey; Irfan Siddiqui; Assad Movahed
Journal:  Eur Heart J Case Rep       Date:  2018-07-31

3.  Ten-year experience of tricuspid valve replacement with the St. Jude medical valve.

Authors:  Xiliang Zhu; Yi Luo; Eryong Zhang; Qi An; Xijun Xiao; Li Dong; Yingqiang Guo; Ke Dian; Zhong Wu
Journal:  Sci Rep       Date:  2018-11-09       Impact factor: 4.379

Review 4.  Diagnosis and surgical treatment for isolated tricuspid Libman-Sacks endocarditis: a rare case report and literatures review.

Authors:  Zhixuan Bai; Jianglong Hou; Wenjun Ren; Yingqiang Guo
Journal:  J Cardiothorac Surg       Date:  2015-07-08       Impact factor: 1.637

Review 5.  Ebstein's anomaly: contemporary management strategies.

Authors:  Sandeep Sainathan; Luciana da Fonseca da Silva; Jose Pedro da Silva
Journal:  J Thorac Dis       Date:  2020-03       Impact factor: 3.005

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.